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Abstract  
Nanomedicine formulations such as biodegradable nanoparticles (nps) and liposomes offer several 
advantages over traditional routes of administration: due to their small size, nanocarriers are able to 
selective accumulate inside tumours or inflammatory tissues, resulting in improved drug efficacy and reduced 
side effects. To further augment targeting ability of nanoparticles towards tumour cells, specific ligands or 
antibodies that selectively recognize biomarkers over-expressed on cancer cells, can be attached to the 
surface either by chemical bond or by hydrophilic/hydrophobic interactions. In the present work, Herceptin 
(HER), a monoclonal antibody (mAb) able to selectively recognize HER-2 over-expressing tumour cells (such 
as breast and ovarian cancer cells) was absorbed on the surface of nanoparticles through 
hydrophilic/hydrophobic interactions. Nps were prepared by a modified single emulsion solvent evaporation 
method with five different polymers: three commercial polyesters (poly(ε-caprolactone) (PCL), poly (D,L-
lactide) (PLA) and poly (D,L-lactide-co-.glycolide) (PLGA)) and two novel biodegradable polyesterurethanes 
(PURs) based on Poly(ε-caprolactone) blocks, synthesized with different chain extenders (1,4-cyclohexane 
dimethanol (CDM) and N-Boc-serinol). Polyurethanes were introduced as matrix-forming materials for 
nanoparticles due to their high chemical versatility, which allows tailoring of the materials final properties by 
properly selecting the reagents. All nps exhibited a small size and negative surface charge, suitable for 
surface functionalisation with mAb through hydrophilic/hydrophobic interactions. The extent of cellular 
internalization was tested on two different cell lines: MCF-7 and SK-BR-3 breast cancer cells showing a 
normal and a high expression of the HER-2 receptor, respectively. Paclitaxel, a model anti-neoplastic drug 
was encapsulated inside all nps and release profiles and cytoxicity on SK-BR-3  cells were also assessed. 
Interestingly, PUR nps were superior to commercial polyester-based nps in terms of higher cellular 
internalization and cytotoxic activity on the tested cell lines. Results obtained warrants further investigation 
on the application of these PUR nps for controlled drug delivery and targeting. 
Keywords Nanoparticles; Polyesterurethanes; Herceptin; Paclitaxel; Cancer Targeting 
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Introduction  
Nano-sized drug delivery systems including nanoparticles, liposomes and micelles, have been widely 
investigated as carriers for various formulations, due to their ability to overcome biological barriers and to 
deliver their content in a controlled manner at the desired place [1-4]. 
Moreover, nanomedicine formulations offer several advantages over traditional routes of administration, such 
as higher drug bioavailability and reduced side effects, since they are able to selectively accumulate into 
specific organs or tissues [1]. Due to their small size nanoparticles can extravasate into the leaky vascular 
endothelium of cancer tissues through the Enhanced Permeability and Retention (EPR) effect, and are 
therefore able to passively target tumour cells [5]. 
Compared to normal tissues, tumours are composed of fast-growing cells which need a high supply of 
oxygen and other nutrients to proliferate and as a result possess highly fenestrated and permeable vessels. 
Particles with size matching the dimensions of these fenestrations (200-500 nm, depending on the tumour 
type) can easily enter cancer cells [5]. Moreover the absence of an efficient lymphatic drainage increases 
particles residence time, and hence activity, inside tumours. 
Several studies have been reported on the preparation of polymeric nano-sized drug carriers for the 
selective delivery of chemotherapy in an attempt to overcome inherent limitations due to the high 
hydrophobicity of the formulations, which results in poor bioavailabilty, high systemic toxicity and scarce 
patient outcome [3, 6]. 
Nanoparticles as drug delivery systems have been reported to offer advantages over free drugs of efficient 
chemotherapy, by virtue of rapid intracellular delivery of the drug [1]. Rapid intracellular delivery is vital, as 
various chemotherapeutic agents act by blocking some critical steps of the cell division process hence 
impairing mitosis and promoting apoptosis [7]. However, non-specific biodistribution and trafficking hampers 
these advantages leading to poor efficacy. To augment the targeting ability of nanoparticles towards tumour 
cells, specific ligands or antibodies that selectively recognize biomarkers over-expressed on cancer cells can 
be attached to the surface, either by chemical bond or by non-specific interactions [8, 9]. 
Targeted delivery of nps to the tumour cells without affecting the healthy cells results in higher therapeutic 
effect and helps mitigate side effects. Among targeting moieties, monoclonal antibodies have been 
extensively applied for their ability to initiate specific signalling cascades resulting in potentiated therapeutic 
effect of drugs [10, 11]. 
In this work, nanoparticles for the controlled delivery of the anti-neoplastic drug Paclitaxel (PAC) were 
prepared by a modified single emulsion method using five different polymers: three commercial polyesters 
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(poly(ε-caprolactone) (PCL), poly (D,L-lactide) (PLA) and poly (D,L-lactide-co-glycolide) (PLGA)) and two 
novel polyesterurethanes (PURs), based on Poly(ε-caprolactone) blocks (in the following referred to as C-
BC2000 and NS-BC2000), synthesized with different chain extenders: 1,4-cyclohexane dimethanol (CDM) 
and N-Boc-serinol for the synthesis of C-BC2000 and NS-BC2000 respectively.  
Polyurethanes are segmented block copolymers with interesting and versatile properties, characterized by a 
two-phase structure composed by hard segment domains embedded into a matrix of soft segments [12, 13]. 
The high chemical versatility of these polymers allows for a fine tuning of their chemical and mechanical 
properties as well as their biological response, making PURs interesting candidates for the preparation of 
highly functionalized nanoparticles. In particular bioactive molecules, such as peptides and proteins, can be 
inserted in the polymer backbone or can be attached to the polymer surface as pendant groups.  
The present work serves as a proof of concept on the possibility of applying PURs for the preparation of  
functionalised nanoparticles for the treatment of cancer. Trastuzumab (Herceptin ®), a recombinant 
humanized IgG1 monoclonal antibody (mAb) used in the treatment of HER-2 over-expressing cancer cells 
such as breast, ovarian and pancreatic cancer cells, was adsorbed on the surface of nps to create 
functionalised carriers for the active targeting of breast cancer cells [14, 15]. Herceptin acts by binding to the 
extracellular domain of the HER-2 receptor and inhibits cell proliferation and survival [16, 17]. In this study, 
Herceptin on the surface of nps was used to target HER-2 expressing cancer cells and to deliver the 
chemotherapeutic agent PAC.   
Functionalised as well as non-functionalised nanoparticles, prepared with the five above-mentioned 
polymers, were incubated in the presence of two different breast cancer cell lines MCF-7 and SK-BR-3, the 
first showing a normal expression (1+) and the second a high over-expression (3+) of the HER-2 receptor 
according to immunohistochemistry test, which measures and scores HER-2 overexpression as negative (0 
or 1+); weakly positive (2+) and strongly positive (3+) [18, 19]. The extent of cellular internalization for 
nanoparticles prepared with different materials and the effect of targeting obtained for mAb-coated carriers 
on SK-BR-3 cells was quantitavely and qualitatively investigated. 
Subsequently the dose response effect of nps containing PAC on the in vitro viability of SK-BR-3 was 
determined. 
Materials & methods 
Materials 
Poly(ε-caprolactone) (PCL, Mw=50000 g/mol) and poly(D,L-lactide) (PLA, Mw=20000-30000 g/mol) were 
purchased from Polysciences Inc., poly (D,L-lactide-co-glycolide) (PLGA 403-H Mw=24000-38000 g/mol) was 
  
- 5 - 
 
purchased from Boeringer Ingelheim-Germany, PCL-diol (Mn=2000 g/mol), 1,4-diisocyanatobutane (BDI), 
1,4-cyclohexane dimethanol (CDM, mixture cis and trans) and N-Boc-serinol were purchased from Sigma 
Aldrich-Italy. 1,4 butanediisocyanate was distilled before use.  Dibutyltin dilaurate (DBTDL, Sigma Aldrich-
Italy) was used as catalyst. 
Phosphate buffer saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), coumarin-6 dye, poly(vinyl 
alcohol) (PVA) were all from Sigma Aldrich. All solvents were of analytical grade. Paclitaxel (PAC) was a kind 
gift from Sorin Biomedica (Italy). Trastuzumab (Herceptin) was a gift from Fannin Compounding Ireland Ltd. 
Milli-Q and deionised water were produced by a Millipore water purification system (Millipore Corporation). 
Polymer Synthesis 
The two polyurethanes used in this study (NS-BC2000, Mn 40000 g/mol and C-BC2000, Mn 35000 g/mol) 
were synthesized following a two step synthesis procedure in inert atmosphere as previously described [20, 
21]; poly(ε-caprolactone) diol and 1,4 butanediisocyanate were used as macrodiol and diisocyanate, 
respectively. The two PURs only differ by the selection of the chain extender: 1,4-cyclohexane dimethanol 
and N-Boc-serinol were used for the synthesis of C-BC2000 and NS-BC2000, respectively. The latter bears 
BOC-protected functional amino groups, which could also be exploited for covalent coupling of targeting 
moieties.  
For the polymer synthesis, the macrodiol was dissolved in 1,2-dichloroethane (DCE) and the solution was 
azeotropically dried for 8 hours. The diisocyanate was then added to the solution (2:1 molar ratio with 
respect to the macrodiol), in the presence of a catalytic amount of DBTDL and reacted with the macrodiol at 
85°C in anhydrous DCE for 150 minutes in order to form an isocyanate-terminated pre-polymer. At the end 
of the pre-polymerization reaction the solution was concentrated and the chain extender was added at 1:1 
molar ratio with respect to the macrodiol, at room temperature. The chain extension reaction was stopped 
after 16 hours by adding methanol. The polymer solution was precipitated in petroleum ether. After drying 
overnight at 40°C under vacuum, the polymer was re-dissolved in dimethylformamide (DMF) and precipitated 
in methanol in order to remove the low molecular weight impurities and residual catalyst. The polymer was 
finally dried at 40°C under vacuum for 24 hours. The molecular weight was assessed by Size Exclusion 
Chromatography (SEC, Agilent Technologies 1200 Series, USA), using a Refractive Index detector and two 
Waters Styragel columns (HT2 and HT4) conditioned at 35°C. Tetrahydrofuran was used as mobile phase at 
a flow rate of 0.5 ml/min and an injection volume of 20μl. 
Polymer Characterization 
FTIR Analysis 
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Attenuated Total Reflectance Fourier Transform Infrared Spectrum (ATR-FT-IR) of the synthesized PURs 
was obtained at room temperature in the spectral range from 4000 to 450 cm-1 using a Perkin Elmer 
Spectrum 100 equipped with an ATR accessory (UATR KRS5) with diamond crystal. The spectrum, obtained 
as a result of 16 scans with a resolution of 4 cm-1, was analyzed with the Perkin Elmer Spectrum software. 
Samples were prepared as films by using conventional solvent-casting techniques starting form a chloroform 
solution at a concentration of 3 %w/v. 
Preparation of nanoparticles  
Nanoparticles were prepared by a Single Emulsion Solvent Extraction Evaporation technique as previously 
described by Ramtoola et al [22] with some modifications, as outlined in figure 1, using ethyl acetate as the 
solvent, deionized distilled water as the non-solvent and poly(vinyl alcohol) as emulsifier. 
Insert Figure 1 
Briefly, 100 mg of the polymer were dissolved in ethyl acetate (4 ml) and added dropwise into 4 ml of water 
containing 2.5% w/v PVA and sonicated for 2 minutes. The primary emulsion was added into 50 ml of water 
containing 1% w/v PVA and homogenized at 13500 rpm. The solution was gently stirred overnight to allow 
solvent evaporation, particles were collected by centrifugation and washed 3 times with distilled water. 
Solutions were then frozen at –80 °C and subsequently freeze dried using a FreeZone 6 Liter Benchtop 
freeze drier (Labconco, Missouri, USA) operating at –56 °C and 0.036 mbar vacuum pressure [16]. 
Preparation of Paclitaxel-loaded nanoparticles 
PAC-loaded nanoparticles (5% w/w with respect to the polymer weight) for in vitro drug release and 
cytotoxicity studies were prepared according to the above-described procedure, by adding the drug to the 
polymer solution in ethyl acetate.  
Preparation of Coumarin-6 loaded nanoparticles 
For cellular uptake/binding analysis, coumarin-6 dye was loaded inside nps. To encapsulate the fluorescent 
dye inside polymer nanocarriers the same protocol described in figure 1 was applied. Briefly the dye (0.5% 
w/v) was dissolved with the polymer in ethyl acetate and the solution was added dropwise into water 
containing the emulsifier, followed by sonication and subsequent homogenization, as previously described.  
Surface modification of nanoparticles 
In order to prepare nanoparticles for the active targeting of HER-positive breast cancer cells, the monoclonal 
antibody Herceptin was introduced on the surface of nanoparticles [14]. Herceptin has an isoeletric point of 
8.45 and it is therefore positively charged at acidic pH. Under these conditions the antibody is expected to 
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react with the negatively charged surface of nanoparticles through electrostatic interaction [23], thus forming 
a coating which may result in enhanced particles uptake by receptor-mediated endocytosis. 
For Herceptin decoration, 500 µl of nanoparticles solution in PBS pH 5.6 (1 mg/ml) were added to the same 
volume of antibody solution (1 mg/ml) and incubated at 4°C for 6 hours. 
The decoration process was first optimized by incubating PLGA nanoparticles in the presence of Herceptin 
for three different time points (1, 6 and 24 hours) at 4°C. The amount of adsorbed protein and the changes in 
the zeta potential and mean diameter of nanoparticles were detected after each time point.  
The amount of the antibody on the surface of nanoparticles was evaluated as the difference between the 
initial and the residual amount of Herceptin in the supernatant, by using bicinchoninic acid (BCA) protein 
assay (Pierce, Rockford, IL). 
Characterization of nanoparticles 
Particle size, size distribution and surface charge  
The particle size and size distribution analysis were performed using a dynamic laser light scattering 
technology (Nanoseries, Nano-ZS; Malvern Instruments, UK). The dispersion of nps was diluted with 
ultrapure water and completely dispersed before measurement. The measured values were averaged by five 
runs.  
Surface charge was determined by electrophoretic light scattering (Nanoseries, Nano-ZS; Malvern 
Instruments, UK) at room temperature in ultrapure water. Results are an average of 5 measurements.  
Determination of Paclitaxel loading and in vitro release profile 
The amount of encapsulated PAC was quantified by using high performance liquid chromatography (HPLC, 
Agilent), equipped with a reversed phase Inertsil C18 column (150x4.6 mm, particles size 5 µm). 5 mg of 
nanoparticles were dissolved in 1 ml dichloromethane (DCM) to extract the encapsulated drug. After DCM 
evaporation, the mobile phase (a mixture of acetonitrile and water in 50% volume ratio) was added. The 
solution was then filtered through a 0.45 µm polyvinylidene fluoride (PVDF) membrane before HPLC 
analysis.  
The encapsulated drug was detected at an absorbance wavelength of 227 nm by means of an UV/VIS 
detector (Libra S22 UV/Visible Spectrophotometer, Biochrom, UK). Drug encapsulation efficiency (EE) was 
determined as follows:  
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where WPACd is the weight (mg) of drug detected by HPLC and WPACt is the theoretical amount of drug 
expected in 5 mg of nanoparticles. 
For the determination of PAC release profiles, 1 mg of nps was accurately weighted, dispersed in distilled 
water (1 ml) and incubated at 37°C under constant shaking. The amount of drug released was measured 
daily for up to 4 days. At the predetermined time points, the solution was centrifuged at 10000 rpm for 15 
minutes and the release medium was replaced with fresh water. 
The drug in the supernatant was extracted by DCM and diluted in the mobile phase. The amount of released 
PAC was measured by HPLC after evaporation of DCM. Samples were analysed in triplicate. 
Cell culture 
SK-BR-3 breast cancer cells, which show high over-expression of HER-2 receptor, were cultured in RPMI-
1640 media supplemented with 10% Heat-Inactivate Foetal Bovine Serum (HI-FBS, Sigma Aldrich, Dublin 
Ireland). MCF-7 breast cancer cells, which show normal expression of HER-2, were cultured in Minimum 
Essential Eagle Medium with Earle’s salts, l-glutamine and sodium bicarbonate containing 10% HI-FBS [24]. 
Cells were propagated in 75cm2  tissue culture flasks in humidified environment at 37°C with 5% CO2. 
Medium was changed every two days and cells were split at a ratio of 1:2 every 4 days when 90% 
confluence was reached. 
In vitro cellular uptake/binding of coumarin-6 loaded nanoparticles 
Extent of in vitro cellular uptake/binding of coumarin-6 loaded nps was investigated by flow cytometry and by 
confocal microscopy by measuring the intensity of the green fluorescence inside the cells. Cells were seeded 
into 24-well plates at 5x103 cells/well and cultivated for 2 days, after which 0.5 ml of coumarin-6 loaded 
nanoparticles suspension (1 mg/ml) in sterile PBS was added to each well containing the cells, keeping a 1:1 
volume ratio between sterile PBS and the cell culture medium. 
After 2 hours of incubation the nps suspension in the testing wells was removed and cells were washed 
three times with sterile PBS to remove unbound nanoparticles. The cells were harvested and fixed with 3.7% 
paraformaldehyde, in order to expose the internalized nanoparticles for the quantitative measurement using 
flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA). The green fluorescence signal produced by 
the coumarin-6 dye loaded nps was investigated by flow cytometry using Fl-1 channel. For each analysis, 
100.000 events were acquired. Data were analysed using the CellQuest Pro software. The experiment was 
carried out in triplicate.  
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Percentage of nanoparticle uptake/binding was determined by the percentage of cells having internalized 
fluorescent nanoparticles, as detected by the peak at the highest fluorescence intensity during flow 
cytometry . 
For confocal study, cells were seeded in a 24-well plate containing ethanol-sterilized coverslips. 0.5 ml of 
coumarin-6 loaded nanoparticles suspension (1 mg/ml) in sterile PBS were added to the cells and incubated 
for 2 hours. After incubation, cells were washed three times with sterile PBS and fixed with 3.7% 
paraformaldehyde for 20 minutes. The nuclei were then stained with Propidium Iodide (PI) for 20 minutes.  
Cells were again washed 3 times with PBS, mounted on the slide by using DAKO® Fluorescent Mounting 
Medium and subsequently observed under confocal laser scanning microscopy (Olympus FV1000 Confocal 
Laser Scanning Microscope). Z-stack images of 10 slices were acquired and results from the top, middle and 
bottom stacks were used to prove cellular internalization of nps.  
 
In vitro cytotoxicity 
For cytotoxicity measurement, SK-BR-3 cells were cultivated in 96-well plates at 5x103 cells/well. After 12 
hours the medium was removed and replaced with a suspension of HER-coated or non-coated nanoparticles 
in sterile PBS. All nanoparticles were sterilized by UV irradiation for 2 hours before use. The effect of three 
different doses (0.25 µg/ml, 1 µg/ml and 2.5 µg/ml) of Paclitaxel was investigated. After 24 hours of 
exposure, the particles suspension was removed and cell viability was assessed by MTS colorimetric assay 
[16]. The absorbance of the wells was read by microplate reader at a wavelength of 490 nm. Cell viability is 
defined as the percentage of viable cells remaining after incubation with various treatments (treated cells), 
compared to control cells (or untreated cells) incubated with medium only under the same conditions and 
was calculated by dividing the absorbance from the treated cells by that of the control cells, multiplied by 
100. The EC50, which represents the half maximal effective concentration which induces a response half 
way between the baseline and maximum response, after specified exposure time, was calculated by the 
non-linear regression (sigmoidal dose-response) using GraphPad (GraphPad Prism Software Inc., San 
Diego, CA, USA).  
 
Statistical analysis 
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The results obtained are expressed as a mean ± standard deviation calculated using Microsoft Excel 
(Redmond, WA, USA) software. Statistical analysis was performed using SPSS version 18.0 for windows 
(SPSS, Inc., Chicago, IL, USA). One-way ANOVA followed by the post hoc analysis (Tukey) were used to 
compare the results. A p value of less than 0.05 was considered as statistically significant. 
 
Results & Discussion 
Polymer characterization 
ATR-FT-IR Analysis 
PURs were successfully synthesized as confirmed by Attenuated Total Reflectance Fourier Transform 
Infrared Spectroscopy (ATR-FT-IR -Perkin Elmer Spectrum 100 UATR KRS5), reported in figure 2. ATR-FT-
IR shows the presence of the characteristic peaks at 1720 cm-1, and 1680 cm-1, associated with the 
absorption of the carbonyl of the ester and the urethane groups respectively. The peak at 3330 and 1535 
cm1 represents the N-H stretching and bending vibrations of urethane linkage, respectively. The absorbance 
at 1160 cm-1 was attributed to C-O stretching in PCL and urethane groups. The conversion of isocyanates 
was quantitative as no diagnostic peaks related to these groups were detected at 2200 cm-1. 
Insert Figure 2 
Preparation of nanoparticles 
Nanoparticles with small size and low polydispersity index (PDI) were successfully obtained with all 
polymers, indicating that the choice of the matrix-forming material did not significantly affect the final 
dimensions and that polyurethanes are suitable candidates for the preparation of small, monodisperse 
nanoparticles by the Single Emulsion Technique.  
The size of nanoparticles was found to be in the range 180 – 200 nm. Among the tested polymers, PCL 
showed the largest particle size (p<0.0001) whereas NS-BC2000 synthesized from PCL blocks showed a 
significantly lower particle size of 180 nm compared to all other polymers (p<0.0001) except for PLGA nps (p 
> 0.05). Moreover, all particles exhibited negative surface charge, ranging from -10 to -25 mV, with PLGA 
showing significantly lower zeta potential (p<0.0001) which is expected to favour surface adsorption of the 
monoclonal antibody Herceptin [14]. 
PAC was also successfully encapsulated inside the carriers. Results from particles size analysis and surface 
charge for plain, Copumarin-6 loaded and PAC-loaded nps are summarized in table 1-3, respectively. The 
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mean particles size ranged from 170 nm to 220 nm for PAC loaded nps. This small size is expected to favour 
cellular internalization by tumour cells through the EPR effect [5]. 
Encapsulation of PAC led to a change in the characteristics of NPs, depending on the type of polymer. While 
no change in size of C-BC2000 and PLGA nps was observed, PAC loading caused an increase in size of 
NS-BC2000 and PLA nps, and a decrease in size for PCL nps. Moreover PAC loading resulted in a change 
in zeta potential which decreased for C-BC2000 and NS-BC2000 and increased for PLGA, PLA and PCL 
nps.   
PLGA nanoparticles showed significantly higher encapsulation efficiency (55.7 ± 6.4 %, table 3) (p<0.05) 
followed by PLA nanoparticles (45.0 ± 4.5%), while PCL and PUR nanoparticles displayed similar values, 
ranging from 30.0 ± 3.7% to 33.8 ±  4.2% The results shown here clearly demonstrate that 
polyesterurethanes are suitable matrix-forming materials for drug nanocarriers, since they perform similarly 
to widely adopted materials such as PLA, PLGA or PCL. 
 
Insert table 1 
Insert Table 2 
Insert Table 3 
 
 
Surface Modification of nanoparticles 
Optimization of the method: effect of the incubation time 
Since PLGA is the most extensively studied polymer for the preparation of nanoparticles [5], the optimal 
incubation time for surface modification was determined on PLGA nanoparticles by detecting the changes in 
particles size and zeta potential as well as the amount of Herceptin present on the surface of the carrier at 
three different time points (1h, 6h and 24h).   
These results are summarized in table 4 before and after incubation with mAb (n=3). 
A significant increase in mean diameter and surface charge of nanoparticles after incubation in the presence 
of Herceptin suggests that the surface has been successfully decorated with the antibody, as reported by 
other authors [25, 26]. The mean diameter increases with increasing incubation time to 6 hours for PLGA 
nanoparticles. After one hour of incubation a large increase of the surface charge was observed from -24.4 
mV to a slightly positive value of 1.4 mV. No further change in zeta potential was detected after increasing 
the incubation time from 1 h to 6 h and 24 h. The amount of adsorbed Herceptin on the surface of 
  
- 12 - 
 
nanoparticles, determined by BCA protein assay, increased with increasing incubation time over the 24 h 
study, as shown in table 4.  
Based on the results, an incubation time of 6 hours was selected to prepare Herceptin-decorated 
nanoparticles using the other four polymers, since it was considered a good balance between neutralisation 
of the zeta potential, acceptable amount of antibody and short incubation time (to reduce undesired PAC 
release). 
Insert Table 4. 
Preparation of HER-coated nanoparticles 
Size and zeta potential analysis of nps prepared with all five polymers before and after 6 hours of incubation 
in the presence of Herceptin for placebo and PAC-loaded nanoparticles are summarized in table 1 and 3, 
respectively. In all cases, adsorption of Herceptin on the nps surface caused a significant increase in their 
zeta potential (p<0.0001).  
This indicates that the surface decoration was achieved successfully, regardless of the presence of the 
anticancer drug, as also confirmed by the increase of the mean diameter and by BCA protein assay.  
PCL and the polyesterurethane NS-BC2000 exhibited significantly higher amount of Herceptin on their 
surface after 6 h incubation (p<0.05), while PLGA had the lowest Herceptin adsorption although the increase 
in zeta potential was the highest. The different nature of the polymers may account for the differences in the 
amount of Ab molecules detected among different polymers, since it has been reported that non-specific 
interactions can also be governed by hydrophobic interactions between the hydrophobic polymers and the 
hydrophobic Fc domain of mAbs.. It is worth noting that nps prepared with the less hydrophobic PLGA 
(contact angle 62°) exhibited remarkably lower Ab coating, compared to the more hydrophobic PLA (82°), 
PCL (89°), NS-BC2000 (78°) and C-BC2000 (91°). 
 
Drug release profiles 
PAC release profiles from nps prepared using the five polymers, before and after HER coating, show that 
PAC release from C-BC2000 nanoparticles was significantly higher than from other non-coated nps (Figure 
3a and 3b). Negligible PAC release was observed from the non-coated PCL nanoparticles after the first day 
of incubation and no PAC release was detected for the decorated carriers over the 4 days studied. Higher 
PAC release was observed from uncoated C-BC2000 carriers with ~35% release observed over 4 days while 
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drug release from uncoated NS-BC2000, PLGA and PLA was between 3-10%. Drug release from HER-
coated nps was minimal except for C-BC2000 where ~8% of drug was released at day 4. 
Insert Figure 3 
A moderate initial PAC burst release at ~16% (day 1) was observed from uncoated C-BC2000 nps, which is 
needed to suppress the growth of cancer cells at the beginning of the treatment [15]. No PAC release was 
observed from Herceptin-coated nps after day 1s, except for NS-BC2000 where ~1% of drug release was 
observed after this time point. Similar drug release was observed by Liu et al. with 20% PLGA-PEG/PLGA 
nps where Herceptin linked to nps decreased the release rate of Docetaxel from the carriers. The layer of 
antibody on the surface of nanoparticles may result in a barrier to water permeation, which decreases the 
rate of hydration of the Nanoparticles surface, thus affecting drug release and lowering the diffusion rate of 
the drug [17]. Indeed, adsorption of the antibody on the NP surface led to an increase in the NP size across 
all polymers ranging from 4 nm for C-BC2000 to 60 nm for PLGA, this layer of antibody may results in a 
decrease in the rate of hydration of the nanoparticles surface, thus affecting drug release. 
 
Quantitative in vitro cellular uptake/binding 
A quantitative measurement of the extent of cellular internalization/binding of coumarin-6 loaded nps  was 
conducted by measuring the intensity of the fluorescence from the carriers taken up by SK-BR-3 and MCF-7 
cell lines using flow cytometry. Courmarin-6 was encapsulated in the particles as a fluorescent marker for 
evaluation of cellular uptake, because of its low leaking rate  (<2.7%) within 2 hours [23]. Results show that 
nps prepared using various polymers were taken up by both MCF-7 and SK-BR-3 cells, regardless of the 
HER coating (figure 4a and 4b). This was related to the small size of these particles at < 242 nm [5]. Percent 
uptake of nps by MCF-7 cells across all the polymers ranged between ~20-40%. HER coated nps showed 
moderately higher cellular uptake in MCF7 compared to the uncoated nps, except for PCL and PLA nps 
(figure 4A). This was expected due to moderate expression of HER2 receptors on MCF-7. Liu et al [17] 
observed a similar trend where after 2h incubation the extent of nps uptake in MCF-7 was independent of 
HER conjugation. Similar results were also reported by Steinhauser et al. [26].  
Uptake of nps by SK-BR-3 cells was higher at >50% (figure  4b) and except for PLA nps, uptake of the HER-
coated carriers was higher than corresponding uncoated ones by 1.2, 1.3 fold, as a result of the targeting 
ability of HER-coated nps to the HER-2 receptors of SK-BR-3. This observation was consistent with the 
literature [19, 23, 26]. Sun et al. reported a 1.1-fold higher uptake of HER adsorbed onto 
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PLGA/Montmorillonite nps, while Liu et al. reported a 1.6-fold increase in particles uptake of chemically 
conjugated HER to PLGA-PEG/PLGA nps for SK-BR-3 cells. Higher extent of HER-coated nps uptake in SK-
BR-3 was attributed to the high over expression of the HER-2 receptors, that facilitate and enhance the 
uptake of mAb-coated particles via receptor mediated endocytosis [17]. Since an increase in cellular uptake 
is observed for both cell lines when HER-coated nps are used, the possibility of unspecific uptake due to 
mAb denaturation cannot be completed excluded [27]. Overall, for both cell lines, a higher cellular 
internalization was observed for nps prepared with the two novel polyesterurethanes. In particular for HER-
coated nanoparticles a significantly higher SK-BR-3 uptake was observed for C-BC2000 and NS-BC2000 
nanoparticles, compared to PLA and PLGA nps.  
Insert Figure 4 
In vitro cellular uptake/binding: confocal microscopy study 
Cellular uptake and targeting efficiency of nps to the breast cancer cells, before and after Herceptin coating 
was investigated by confocal microscopy. Results from confocal analysis were found to be similar to the 
results from flow cytometry studies. A strong green fluorescence intensity was observed from SK-BR-3 cells 
compared to MCF-7, indicative of higher nps uptake in SK-BR-3 cells (figure 5 and 6). Nps were mainly 
localized in the cell’s cytoplasm, since the nucleus (red) appears circumvented by the green fluorescence of 
the coumarin-6 dye present inside the particles.  
Sun et al [23] treated SK-BR-3 with PLGA/montmorillonite nps, with and without Trastuzumab decoration 
and observed particles  uptake in both cytoplasm and nucleus, while Liu et al. [17] observed uptake of 
PLGA-PEG/PLGA nps mainly in cytoplasm of SK-BR-3 cells, regardless of the HER functionalization. 
Confocal microscopy for both MCF-7 and SK-BR-3 cell lines clearly showed higher-intensity green 
fluorescence for HER-coated nps than corresponding uncoated ones, indicating enhanced uptake of HER- 
coated nps. SK-BR-3 cell line showed higher uptake than MCF-7 for HER- coated carriers as a result of 
HER-2 receptors over-expressed by these cells. This is in agreement with Liu et al. [17], who reported that 
ligand conjugation can also enhance internalisation of nps in the moderately HER-2 expressing MCF-7, 
provided that the quantity of ligand on the surface is high enough. In our study, Herceptin decoration 
facilitated cellular delivery of nps in both breast cancer cells, especially for SK-BR-3 cells. 
Insert Figure 5 
Insert Figure 6 
In vitro cytotoxicity 
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In order to evaluate the cytotoxic efficacy of the carriers, PAC-containing nps were prepared with and without 
HER coating and quantitative analysis of PAC on the cytotoxicity on SK-BR-3 cells was performed. The cells 
were incubated with various nps for 24 hours and the percent cell viability, calculated by taking untreated 
cells not exposed to nanoparticles as 100% viable, are shown in Figure 7a and 7b.    
Cell viability of HER-coated nps without PAC was found to be similar to the corresponding uncoated nps 
across all the polymers (ANOVA, post hoc, p>0.05) with an exception of HER-coated PCL nps which showed 
a significant decrease in cell viability compared to uncoated PCL nps for SK-BR-3 cells (ANOVA, post hoc, p 
< 0.05). This can be related to the difference in the extent of HER coating onto the PCL nps. The amount of 
antibody on PCL carriers was the highest at 3.9 μg/0.5 mg nps (table 2). Among PAC-loaded nps, HER-
coated PCL nps showed a lower cytotoxic effect compared to their non-coated counterpart, probably due to 
the slower drug release which results in reduced short-term cytotoxic effects of these nps, as shown by our 
release experiments (figure  3). 
Uncoated nps showed a dose-dependent cytotoxic effect across all polymers. The percent of living cells 
decreased linearly with increasing PAC dose. Nps prepared by C-BC2000 showed the highest cytotoxic 
activity against SK-BR-3 tumour cells at the highest PAC doses (p < 0.05). This result is in agreement with 
the faster drug release observed from carriers prepared with this polymer. 
The cytotoxic effects of HER-coated nps were lower than for uncoated particles, probably because of the 
lower drug release profiles observed from antibody-coated nps. Indeed, the presence of the mAb resulted in 
a delayed release of the encapsulated PAC, especially during the first day. 
Insert Figure 7 
The IC50 of uncoated C-BC2000 nps was found to be the lowest at 2.5 µg/ml compared to the other 
uncoated nps evaluated in the present study, indicating that C-BC2000 nps are effective at lower PAC 
doses. This effect could be partly due to their high uptake efficiency and partly to the higher PAC release.  
IC50 for HER coated nps was higher across all polymers, even though HER coated nps showed higher 
uptake efficiency compared to corresponding uncoated particles as observed earlier. This result could be 
explained with a reduced PAC release because of the antibody coating .  
In literature [23] the IC50 of the drug, taxol®, is reported to be higher at 17.43 µg/ml while that of 
PLGA/montmorillonite nps was 16.94 µg/ml. IC50 of uncoated C-BC2000 nps investigated in this study was 
much lower at 2.5 µg/ml. Hence it can be speculated that the novel C-BC2000 polymer can be effectively 
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used for more efficient delivery of PAC to breast cancer cells. This novel polymer can also be used for drug 
delivery to other diseased organs and warrants further investigation.  
 
Conclusions 
Nanoparticles with different polymers were successfully prepared by a modified single emulsion solvent 
extraction evaporation method and surface-modified with mAb, to increase targeting ability of HER-2 over-
expressing breast cancer cells For this purpose, Herceptin, a monoclonal antibody known to selective bind to 
HER-2 over-expressing cells, like pancreatic and breast cancer cells, was introduced on the surface of nps 
as a coating, through non-specific interactions between the negatively charged polymer surface and the 
positively charged protein at an appropriate pH. Regardless of the polymer used, all particles exhibited an 
adequate size for the passive targeting of cancer cells through the EPR effect [4]. Surface modification was 
successfully achieved, as demonstrated by changes in size and zeta potential of the particles [25, 26]. The 
amount of Herceptin on the surface, measured by Bicinchoninic acid (BCA) protein assay, confirmed the 
presence of the antibody on nanoparticles. Two different breast cancer cell lines were selected to measure 
nps uptake: MCF-7 which have moderate expression of the HER-2 receptor and SK-BR-3, which exhibit high 
over-expression of the same receptor. Uptake by MCF7 cells was consistent across all polymers with 
percent uptake ranging between ~20-40%. A moderate increase in cellular uptake was observed for HER 
coated NPs compared to the uncoated counterparts, except for PCL nps.  
On the other hand, nps uptake was higher at >50% on SK-BR-3 cells. Except for PLA nps, uptake of the 
HER-coated carriers was higher than corresponding uncoated ones by 1.2-1.3 fold, as a result of the 
targeting ability of HER-coated nps to the HER-2 receptors of SK-BR3.  
Among the polymers examined, the two novel biodegradable polyesterurethanes exhibited higher cellular 
internalization, targeting ability and cytotoxic activity on SKBR-3 cells. These results indicate that these new 
materials show superior properties, when compared to standard, traditionally used matrix-forming materials. 
Moreover, one of the 2 new polyurethanes (NS-BC2000) possesses protected functional amino groups (NH2) 
which can be exploited for future chemical coupling of antibodies or other targeting moieties allowing more 
specific targeting of therapeutics [28]. Their potential as matrix-forming materials for novel nanomedicine 
formulations warrants further exploration. 
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FIGURE CAPTIONS 
Figure 1. Schematic representation of the protocol adopted for the preparation of nanoparticles. The polymer and the 
drug were dissolved in a common solvent (ethyl acetate) and emulsified by sonication into a solution of water and PVA at 
high concentration (2.5 % w/v). The emulsion was the poured into 50 ml of water containing PVA (1 % w/v) and 
homogenized to further reduce nps size. Solvent evaporation was allowed by overnight stirring at room temperature.   
Figure 2  ATR-FT-IR Analysis of the polyurethanes C-BC2000 and NS-BC2000. Characteristic absorption peaks at 1720 
cm-1 (carbonyl of the ester groups), 1680 cm-1 (carbonyl of the urethane group), 3330 cm-1  (NH stretching of urethane 
group), 1535 cm-1 (NH bending of urethane group) and 1160 cm-1 (C-O stretching of ester and urethane groups) are 
indicated.   
Figure 3 Release profiles from HER-coated (A) and non-coated (B) nanoparticles prepared with different polymers, 
during 4 days of incubation in water (n=3). The presence of the antibody on the surface of the carriers reduces water 
permeation in the polymer matrix, lowering the diffusion rate of PAC. 
Figure 4 Cellular uptake efficiency of dye-loaded, Herceptin-coated and uncoated particles (1mg/ml) prepared with 
different polymers, for MCF 7 (A) and SK-BR-3 (B) cells, measured by flow cytometry after 2 h of incubation.  
Figure 5 Confocal microscopy on MCF-7 cells: images are obtained from the upper, middle and bottom stack from the 
merged channels for red (nuclei) and green (Coumarin dye inside nanoparticles) (magnification 600X) for both plain 
nanoparticles and Herceptin-coated nps. Scale bars represent 30 µm. 
Figure 6 Confocal microscopy on SK-BR-3 cells: images are obtained from the upper, middle and bottom  stack from the 
merged channels for red (nuclei) and green (Coumarin dye inside nanoparticles). (magnification 600X). for both plain 
nanoparticles and Herceptin-coated nps. Scale bars represent 30 µm. 
Figure 7 Cytotoxicity of different PAC-loaded nps on SK-BR-3 cells after 24 h of incubation for: A) non coated particles 
and B) Herceptin coated nanoparticles.  
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TABLE CAPTIONS 
Table 1 Characterization of both plain and HER-coated placebo nps prepared with different polymers.  
Table 2 Characterization of both plain and HER-coated Coumarin-6 loaded nps prepared with different polymers. 
Table 3 Characterization of both plain and HER-coated PAC-loaded nps prepared with different polymers. 
Table 4 Size, PDI, zeta potential and amount of Herceptin on the surface of PLGA nps after incubation in the presence of 
mAb at different time points. 
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LIST OF TABLES 
 
Material Placebo particles HER-coated particles 
 Size  (nm) PDI Zeta 
Pot. 
(mV) 
Size  
(nm) 
PDI Zeta 
Pot. 
(mV) 
HER 
on 
surface 
(µg/0.5 
mg) 
C-BC2000 200 ± 2 0.11 ± 
0.02 
-12.2 
± 0.6 
200 ± 2 0.12 ± 
0.05 
-5.3 ± 
0.4 
1.3 ± 
0.8 
NS-
BC2000 
180 ± 1 0.11 ± 
0.03 
-9.4 ± 
0.4 
220 ± 12 0.15 ± 
0.01 
-3.5 ± 
1.1 
3.9 ± 
0.6 
PCL 200 ± 3 0.06 ± 
0.01 
-9.6 ± 
0.4 
240 ± 4 0.07 ± 
0.01 
-1.1 ± 
0.1 
4.2 ± 
0.6 
PLGA 180 ± 1 0.07 ± 
0.03 
-24.4 
± 0.4 
240 ± 2 0.17 ± 
0.03 
-0.4 ± 
0.1 
0.7 ± 
0.5 
PLA 190 ± 2 0.14 ± 
0.02 
-22.0 
± 0.9 
230 ± 2 0.13 ± 
0.03 
-0.7 ± 
0.1 
2.5 ± 
0.2 
 
Table 1 
 
Material Coumarin-6 loaded particles HER-coated  Coumarin-6 loaded  
particles 
Size  (nm) PDI Zeta 
Pot. 
(mV) 
Size  (nm) PDI Zeta 
Pot. 
(mV) 
HER 
on 
surface 
(µg/0.5 
mg) 
C-BC2000 190 ± 5 0.04 ± 
0.02 
-13.1 
± 0.2 
210 ± 4 0.06 ± 
0.01 
-6.1 ± 
0.6 
1.1 ± 
0.3 
NS-
BC2000 
170 ± 2 0.09 ± 
0.01 
-9.0 ± 
0.5 
190 ± 3 0.09 ± 
0.03 
-5.7 ± 
0.8 
3.2 ± 
0.5 
PCL 210 ± 4 0.02 ± 
0.01 
-8.9 ± 
0.3 
240 ± 5 0.04 ± 
0.01 
-1.4 ± 
0.1 
3.8 ± 
0.7 
PLGA 180 ± 1 0.09 ± 
0.02 
-23.8 
± 0.3 
250 ± 4 0.20 ± 
0.03 
-0.7 ± 
0.4 
1.0 ± 
0.6 
PLA 200 ± 3 0.03 ± 
0.02 
-24.0 
± 1.0 
240 ± 3 0.05 ± 
0.02 
-1.1 ± 
0.2 
3.0 ± 
0.8 
 
Table 2 
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Material PAC-loaded particles HER-coated PAC-loaded 
particles 
Size  (nm) PDI Zeta 
Pot. 
(mV)
EE 
% 
Size  
(nm) 
PDI Zeta 
Pot. 
(mV) 
HER 
on 
surface 
(µg/0.5 
mg) 
C-BC2000 200 ± 3 0.06 
± 
0.03
-
17.5 
± 0.4
33.8 
± 
4.2 
200 ± 2 0.08 
± 
0.03 
-1.1 
± 0.2 
1.0 ± 
0.6 
NS-
BC2000 
190 ± 1 0.02 
± 
0.01
-
12.8 
± 0.5
38.9 
± 
9.3 
200 ± 3 0.05 
± 
0.02 
-1.4 
± 0.1 
3.5 ± 
1.1 
PCL 170 ± 1 0.03 
± 
0.02
-6.3 
± 1.1
30.0 
± 
3.7 
180 ± 2 0.09 
± 
0.02 
-3.1 
±0.4 
3.9 ± 
0.9 
PLGA 180 ± 2 0.14 
± 
0.01
-
13.2 
± 0.9
55.7 
± 
6.4 
180 ± 1 0.14 
± 
0.02 
-1.0 
± 0.1 
0.8 ± 
0.3 
PLA 220 ± 9 0.29 
± 
0.02
-
18.0 
± 2.9
45.0 
± 
4.5 
230 ± 3 0.08 
± 
0.03 
-2.3 
± 0.4 
2.7 ± 
0.4 
 
Table 3 
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Table 4 
 
 
 
 
 
 
 
 
 
 
Incubation time 
(h) 
Adsorbed HER 
(µg/0.5 mg 
nps) 
Size (nm) PDI Zeta Pot. (mV) 
0 0 182 ± 1 0.07 ± 0.03 -24.4 ± 0.4 
1 0.5 ± 0.3 220 ± 4 0.14 ± 0.01 1.4 ± 0.2 
6 0.7 ± 0.5 242 ± 2 0.17 ± 0.03 -0.4 ± 0.1 
24 1.8 ± 0.9 240 ± 3 0.15 ± 0.02 -0.2 ±0.1 
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